Abiopharma

SAGIMET BIOSCIENCES INC. (SGMT)

Symbol	SGMT
Name	SAGIMET BIOSCIENCES INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Pharmaceutical Preparations
Address	155 BOVET ROAD,SUITE 303, SAN MATEO, California, 94402, United States
Telephone	+1 650 561-8600
Fax	—
Email	—
Website	https://www.sagimet.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001400118
Description	Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. Additional info from NASDAQ: Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

2026-06-29 11:00

Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes

2026-06-23 00:49

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2026-06-15 20:23

Director SEIDENBERG BETH C 🟢 acquired 39.6K shares (1 derivative) of Sagimet Biosciences Inc. (SGMT) at $6.48 Transaction Date: Jun 12, 2026 | Filing ID: 074055

2026-06-15 20:22

Director Hoelscher Paul W. 🟢 acquired 39.6K shares (1 derivative) of Sagimet Biosciences Inc. (SGMT) at $6.48 Transaction Date: Jun 12, 2026 | Filing ID: 074052

2026-06-15 20:21

Director Jarrett Jennifer 🟢 acquired 39.6K shares (1 derivative) of Sagimet Biosciences Inc. (SGMT) at $6.48 Transaction Date: Jun 12, 2026 | Filing ID: 074050

2026-06-15 20:20

Director GRAMMER ELIZABETH A 🟢 acquired 39.6K shares (1 derivative) of Sagimet Biosciences Inc. (SGMT) at $6.48 Transaction Date: Jun 12, 2026 | Filing ID: 074047

2026-06-15 20:20

Director Kemble George 🟢 acquired 39.6K shares (1 derivative) of Sagimet Biosciences Inc. (SGMT) at $6.48 Transaction Date: Jun 12, 2026 | Filing ID: 074045

2026-06-15 20:19

Director Phillips Anne M. 🟢 acquired 39.6K shares (1 derivative) of Sagimet Biosciences Inc. (SGMT) at $6.48 Transaction Date: Jun 12, 2026 | Filing ID: 074044

2026-06-12 20:06

(99% Neutral) SAGIMET BIOSCIENCES INC. (SGMT) Announces Executive Departure

2026-06-02 01:16

Chauche Thierry 🟢 acquired 50.0K shares (1 derivative) of Sagimet Biosciences Inc. (SGMT) at $7.27 Transaction Date: May 28, 2026 | Filing ID: 069124

Trial ID	Title	Phase	Indication	Status	Start Date	Completion Date	Source
NCT07216313	A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Pa…	Phase1	Healthy	Completed	2025-09-30	2025-10-20	ClinicalTrials.gov
NCT06989840	Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in H…	Phase1	Acne	Recruiting	2025-06-03	2027-01-01	ClinicalTrials.gov
NCT06692283	A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients W…	Phase3	MASLD	Withdrawn	2025-03-01	2027-06-01	ClinicalTrials.gov
NCT06594523	A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients W…	Phase3	MASH	Withdrawn	2025-03-01	2030-12-01	ClinicalTrials.gov
NCT05743621	Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer	Phase1	Prostatic Neoplasms, Castration-Resistant	Recruiting	2023-11-20	2029-01-25	ClinicalTrials.gov
NCT05835180	A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild…	Phase1	Non-alcoholic Steatohepatitis	Completed	2023-05-01	2023-12-18	ClinicalTrials.gov
NCT05657834	Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 …	Phase1	Healthy Volunteers	Completed	2022-11-21	2022-12-21	ClinicalTrials.gov
NCT04906421	Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)	Phase2	Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease	Completed	2021-08-12	2023-10-02	ClinicalTrials.gov
NCT03808558	Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas	Phase2	KRAS Gene Mutation	Active_Not_Recruiting	2019-09-11	2026-12-01	ClinicalTrials.gov
NCT03938246	Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)	Phase2	MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)	Completed	2019-03-22	2021-10-02	ClinicalTrials.gov
NCT02948569	Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects Wit…	Phase1	Metabolic Syndrome	Completed	2017-02-01	2019-01-30	ClinicalTrials.gov
NCT02223247	A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patient…	Phase1	Solid Malignant Tumor	Completed	2013-11-01	2017-06-01	ClinicalTrials.gov

Total clinical trials: 12

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
Placebo	Other	Phase PHASE1	Acne	RECRUITING	NCT06989840
TVB-3567	Other	Phase PHASE1	Acne	RECRUITING	NCT06989840
TVB-2640	Other	Phase PHASE2	KRAS Gene Mutation	ACTIVE_NOT_RECRUITING	NCT03808558
TVB-2640	Other	Phase PHASE2	KRAS Gene Mutation	ACTIVE_NOT_RECRUITING	NCT03808558
TVB-2640	Other	Phase PHASE2	KRAS Gene Mutation	ACTIVE_NOT_RECRUITING	NCT03808558
TVB-2640	Other	Phase PHASE2	KRAS Gene Mutation	ACTIVE_NOT_RECRUITING	NCT03808558
TVB-2640	Other	Phase PHASE2	KRAS Gene Mutation	ACTIVE_NOT_RECRUITING	NCT03808558
Placebo	Other	Phase PHASE3	MASLD	WITHDRAWN	NCT06692283
denifanstat	Other	Phase PHASE3	MASLD	WITHDRAWN	NCT06692283
TVB-2640	Other	Phase PHASE1	Solid Malignant Tumor	COMPLETED	NCT02223247
[14C]-TVB-2640	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT05657834
TVB-2640 - 50 mg	Other	Phase PHASE1	Non-alcoholic Steatohepatitis	COMPLETED	NCT05835180
TVB-2640 75 mg (US)	Other	Phase PHASE2	MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)	COMPLETED	NCT03938246
Placebo (China)	Other	Phase PHASE2	MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)	COMPLETED	NCT03938246
TVB-2640 50 mg (China)	Other	Phase PHASE2	MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)	COMPLETED	NCT03938246
Placebo (US)	Other	Phase PHASE2	MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)	COMPLETED	NCT03938246
TVB-2640 50 mg (US)	Other	Phase PHASE2	MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)	COMPLETED	NCT03938246
TVB-2640 25 mg (US)	Other	Phase PHASE2	MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)	COMPLETED	NCT03938246
3-V Bioscience-2640	Other	Phase PHASE1	Metabolic Syndrome	COMPLETED	NCT02948569
Placebo	Other	Phase PHASE2	Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease	COMPLETED	NCT04906421
TVB-2640	Other	Phase PHASE2	Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease	COMPLETED	NCT04906421
Placebo	Other	Phase PHASE3	MASH	WITHDRAWN	NCT06594523
Denifanstat	Other	Phase PHASE3	MASH	WITHDRAWN	NCT06594523
Enzalutamide	Other	Phase PHASE1	Prostatic Neoplasms, Castration-Resistant	RECRUITING	NCT05743621
TVB-2640	Other	Phase PHASE1	Prostatic Neoplasms, Castration-Resistant	RECRUITING	NCT05743621
TVB-2640	Other	Phase PHASE2	KRAS Gene Mutation	ACTIVE_NOT_RECRUITING	NCT03808558
Resmetirom	Other	Phase PHASE1	Healthy	COMPLETED	NCT07216313
Denifanstat	Other	Phase PHASE1	Healthy	COMPLETED	NCT07216313
Placebo	Other	Phase PHASE1	Acne	RECRUITING	NCT06989840
TVB-3567	Other	Phase PHASE1	Acne	RECRUITING	NCT06989840
Resmetirom	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT07216313
TVB-3567	DRUG	Phase PHASE1	Acne	RECRUITING	NCT06989840
denifanstat	DRUG	Phase PHASE3	MASLD	WITHDRAWN	NCT06692283
Denifanstat	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT07216313
TVB-2640 - 50 mg	DRUG	Phase PHASE1	Non-alcoholic Steatohepatitis	COMPLETED	NCT05835180
Enzalutamide	DRUG	Phase PHASE1	Prostatic Neoplasms, Castration-Resistant	RECRUITING	NCT05743621
[14C]-TVB-2640	DRUG	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT05657834
Placebo	DRUG	Phase PHASE1	Acne	RECRUITING	NCT06989840
TVB-2640 75 mg (US)	DRUG	Phase PHASE2	MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)	COMPLETED	NCT03938246
Placebo (China)	DRUG	Phase PHASE2	MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)	COMPLETED	NCT03938246
TVB-2640 50 mg (China)	DRUG	Phase PHASE2	MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)	COMPLETED	NCT03938246
Placebo (US)	DRUG	Phase PHASE2	MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)	COMPLETED	NCT03938246
TVB-2640 50 mg (US)	DRUG	Phase PHASE2	MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)	COMPLETED	NCT03938246
TVB-2640 25 mg (US)	DRUG	Phase PHASE2	MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)	COMPLETED	NCT03938246
3-V Bioscience-2640	DRUG	Phase PHASE1	Metabolic Syndrome	COMPLETED	NCT02948569
TVB-2640	DRUG	Phase PHASE1	Prostatic Neoplasms, Castration-Resistant	RECRUITING	NCT05743621

Total products: 46